Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer
 >   > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here
 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
 >  > 
 
Follow northcote_b on Twitter
AstraZeneca
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: Level 9 2 Kingdom Street
London
W2 6BD
Index: To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.
Tel: +44 (0)20 7604 8000 Sector:
Fax: +44 (0)20 7604 8270
E-Mail: IR@astrazeneca.com Epic:
Secretary: Adrian Kemp    
Registrar: Equiniti Ltd Updated:

News from RSS Feed

Thu, 22 Jan 2015 04:32:24 +0000

Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency

AstraZeneca today announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets. Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.

Company Overview

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2012 in PDF 31/12/2012 31/01/2013 Yes  
bullet point Annual Report 2011 in PDF 31/12/2011 2/02/2012 No  
bullet point Annual Report 2010 in PDF 31/12/2010 27/01/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 28/01/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 29/01/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 31/01/2008 No  
bullet point Annual Report 2006 in PDF 31/12/2006 1/02/2007 No  
bullet point Annual Report 2005 in PDF (1.92Mb) 31/12/2005 2/02/2006 No  
bullet point Annual Report 2004 in PDF (0.93Mb) 31/12/2004 27/01/2005 No  
bullet point Annual Report 2003 in PDF (0.8Mb) 31/12/2003 29/01/2004 No  
bullet point Annual Report 2002 part 1 in PDF (0.09Mb) 31/12/2002 30/01/2003 No  
bullet point Annual Report 2002 part 2 in PDF 31/12/2002 30/01/2003 No  
bullet point Annual Report 2001 part 1 in PDF (0.01Mb) 31/12/2001 31/01/2002 No  
bullet point Annual Report 2001 part 2 in PDF 31/12/2001 31/01/2002 No  
bullet point Annual Report 2000 - Part 1 in PDF (0.01Mb) 31/12/2000 7/02/2001 No  
bullet point Annual Report 2000 - Part 2 in PDF (0.02Mb) 31/12/2000 7/02/2001 No  
bullet point Annual Report 1999 - Part 1 in PDF (0.61Mb) 31/12/1999 23/02/2000 No  
bullet point Annual Report 1999 - Part 2 in PDF (0.61Mb) 31/12/1999 23/02/2000 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2012 in PDF 30/06/2012 26/07/2012 Yes  
bullet point Interim Results 2011 figures in PDF 30/06/2011 28/07/2011 No  
bullet point Interim Results 2011 narrative in PDF 30/06/2011 28/07/2011 No  
bullet point Interim Results 2010 - Figures in PDF 30/06/2010 29/07/2010 No  
bullet point Interim Results 2010 - Narrative in PDF 30/06/2010 29/07/2010 No  
bullet point Interim Results 2009 - Figures in PDF 30/06/2009 30/07/2009 No  
bullet point Interim Results 2009 - Narrative in PDF 30/06/2009 30/07/2009 No  
bullet point Interim Results 2008 - Figures in PDF 30/06/2008 31/07/2008 No  
bullet point Interim Results 2008 - Narrative in PDF 30/06/2008 31/07/2008 No  
bullet point Interim Results 2007 - Figures in PDF 30/06/2007 26/07/2007 No  
bullet point Interim Results 2007 - Narrative in PDF 30/06/2007 26/07/2007 No  
bullet point Interim Results 2006 - Figures in PDF 30/06/2006 27/07/2006 No  
bullet point Interim Results 2006 - Narrative in PDF (0.16Mb) 30/06/2006 27/07/2006 No  
bullet point Interim Results 2005 - Figures in PDF (0.09Mb) 30/06/2005 28/07/2005 No  
bullet point Interim Results 2005 - Narrative in PDF (0.06Mb) 30/06/2005 28/07/2005 No  
bullet point Interim Results 2004 - Figures in PDF (0.11Mb) 30/06/2004 22/07/2004 No  
bullet point Interim Results 2004 - Narrative in PDF (0.14Mb) 30/06/2004 22/07/2004 No  
bullet point Interim Results 2003 - Figures in PDF (0.09Mb) 30/06/2003 24/07/2003 No  
bullet point Interim Results 2003 - Narrative in PDF (0.13Mb) 30/06/2003 24/07/2003 No  
bullet point Interim Results 2002 - Figures in PDF (0.05Mb) 30/06/2002 25/07/2002 No  
bullet point Interim Results 2002 - Narrative in PDF (0.05Mb) 30/06/2002 25/07/2002 No  
bullet point Interim Results 2001 - Figures in PDF (0.25Mb) 30/06/2001 26/07/2001 No  
bullet point Interim Results 2001 - Narrative in PDF (0.05Mb) 30/06/2001 26/07/2001 No  
bullet point Interim Results 2000 - Figures in PDF (0.05Mb) 30/06/2000 1/08/2000 No  
bullet point Interim Results 2000 - Narrative in PDF (0.04Mb) 30/06/2000 1/08/2000 No  
bullet point Interim Results 1999 - Figures in PDF (0.02Mb) 30/06/1999 3/08/1999 No  
bullet point Interim Results 1999 - Narrative in PDF (0.03Mb) 30/06/1999 3/08/1999 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Results Index
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 15/09/2014 53.1 p
Interim 24/03/2014 116.8 p
Interim 16/09/2013 59.2 p
Interim 18/03/2013 120.5 p
Interim 10/09/2012 58.1 p
Interim 19/03/2012 123.6 p
Interim 12/09/2011 51.9 p
Interim 14/03/2011 116.7 p
Interim 13/09/2010 44.9 p
Interim 15/03/2010 105.4 p
Interim 14/09/2009 0.59 c USD
Interim 14/09/2009 27.8 p
Interim 14/09/2009 36 p
Interim 16/03/2009 104.8 p
Interim 15/09/2008 27.8 p
Interim 17/03/2008 67.7 p
Interim 17/09/2007 25.3 p
Interim 19/03/2007 63 p
Interim 18/09/2006 26.6 p
Interim 20/03/2006 51.8 p
Interim 19/09/2005 21.9 p
Interim 21/03/2005 34.3 p
Interim 20/09/2004 16 p
Interim 6/04/2004 29.4 p
Interim 6/10/2003 15.9 p
Interim 7/04/2003 28.5 p
Interim 7/10/2002 14.7 p
Interim 8/04/2002 33.2 p
Interim 5/10/2001 16.1 p
Interim 9/04/2001 32.1 p
Interim 23/10/2000 15.3 p
Interim 17/04/2000 29.1 p
Interim 25/10/1999 14.2 p

News from RSS Feed

Thu, 22 Jan 2015 04:32:24 +0000

Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency

AstraZeneca today announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets. Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.
Wed, 14 Jan 2015 07:30:00 +0000

PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses

AstraZeneca today announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint. The study assessed BRILINTA® (ticagrelor) tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint was a composite of cardiovascular (CV) death, myocardial infarction (MI) or stroke.
Mon, 12 Jan 2015 07:00:00 +0000

MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV).  The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.
Fri, 19 Dec 2014 17:29:57 +0000

LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA™ (olaparib) capsules (400mg twice daily) as the first monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm)  advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Olaparib has been approved under the FDA’s Accelerated Approval programme, based on existing objective response rate and duration of response data.  Continued approval for this indication is contingent upon verification of clinical benefit in ongoing confirmatory Phase III trials.
Thu, 18 Dec 2014 04:43:24 +0000

Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer

AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorisation for Lynparza™ (olaparib) capsules (400mg twice daily) as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.
Thu, 11 Dec 2014 14:09:18 +0000

AstraZeneca and Amgen to present detailed results from Phase III AMAGINE-1™ study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis

AstraZeneca and Amgen today announced that additional results from AMAGINE-1™, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in patients with moderate-to-severe plaque psoriasis will be presented at the Psoriasis: From Gene to Clinic International Congress in London on Saturday, 13 December 2014 at 11:20 am GMT (Abstract FC30). Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 cytokines (A, F and A/F) to the receptor. The IL-17 receptor and cytokine family play a central role in development and clinical manifestations of plaque psoriasis.
Tue, 9 Dec 2014 07:00:00 +0000

MOVENTIG® approved in the European Union for opioid-induced constipation

AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).
Fri, 5 Dec 2014 12:03:09 +0000

Jury verdict favours AstraZeneca in Nexium antitrust litigation

AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of AstraZeneca in a Multi-District antitrust case filed by various purchaser groups challenging the previous settlement of Nexium patent litigation with Ranbaxy.
Tue, 2 Dec 2014 04:34:39 +0000

New Drug Application for IRESSA accepted by US Food and Drug Administration

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC), as identified through a companion diagnostic test. The Prescription Drug User Fee Act goal date for IRESSA will be in the third quarter 2015.
Mon, 1 Dec 2014 04:45:53 +0000

AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease

AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.


transparent spacer